Silence Therapeutics (STU:XRP2) Cyclically Adjusted Book per Share: €1.85 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:XRP2 Silence Therapeutics PLC STU:XRP2
51 GF Score
Price €8.40
GF Value €0.28
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Cyclically Adjusted Book per Share?

Silence Therapeutics STU:XRP2 +2.44% 51 Cyclically Adjusted Book per Share is €1.85 as of Mar. 2026. GuruFocus rates STU:XRP2 with a GF Score™ of 51/100 and a GF Value™ of €0.28 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Silence Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €0.905. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.85 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Silence Therapeutics's average Cyclically Adjusted Book Growth Rate was -58.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -45.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -36.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Silence Therapeutics was -20.30% per year. The lowest was -45.10% per year. And the median was -30.50% per year.

As of today (2026-07-15), Silence Therapeutics's current stock price is €8.40. Silence Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.85. Silence Therapeutics's Cyclically Adjusted PB Ratio of today is 4.54.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 5.44. The lowest was 0.13. And the median was 0.82.


Silence Therapeutics  (STU:XRP2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Silence Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=8.40/1.85
=4.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Silence Therapeutics was 5.44. The lowest was 0.13. And the median was 0.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Silence Therapeutics Cyclically Adjusted Book per Share Related Terms


Silence Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Cyclically Adjusted Book per Share Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 36.65 5.48 2.53

Silence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 4.85 3.79 2.53 1.85

STU:XRP2 vs IMRX, VRXA, MGNX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Silence Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:XRP2
51GF Score
Silence Therapeutics PLC STU:XRP2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Silence Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.905/140.8000*140.8000
=0.905

Current CPI (Mar. 2026) = 140.8000.

Silence Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201206 2.624 95.600 3.865
201212 3.024 97.300 4.376
201306 2.753 98.000 3.955
201312 2.267 99.200 3.218
201406 2.555 99.800 3.605
201412 2.085 99.900 2.939
201506 4.486 100.100 6.310
201512 3.851 100.400 5.401
201606 2.934 101.000 4.090
201612 2.724 102.200 3.753
201706 2.413 103.500 3.283
201712 2.564 105.000 3.438
201806 2.108 105.900 2.803
201812 1.668 107.100 2.193
201906 1.283 107.900 1.674
201912 0.985 108.500 1.278
202006 1.124 108.800 1.455
202009 0.000 109.200 0.000
202012 0.365 109.400 0.470
202103 0.000 109.700 0.000
202106 0.909 111.400 1.149
202109 0.624 112.400 0.782
202112 0.340 114.700 0.417
202203 0.159 116.500 0.192
202206 -0.182 120.500 -0.213
202209 1.072 122.300 1.234
202212 0.702 125.300 0.789
202303 0.533 126.800 0.592
202306 0.388 129.400 0.422
202309 0.591 130.100 0.640
202312 0.509 130.500 0.549
202403 3.090 131.600 3.306
202406 2.825 133.000 2.991
202409 2.414 133.500 2.546
202412 2.710 135.100 2.824
202503 -2.208 136.100 -2.284
202506 1.728 138.400 1.758
202509 1.336 138.900 1.354
202512 1.126 139.900 1.133
202603 0.905 140.800 0.905

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.85 mean?
Silence Therapeutics (STU:XRP2) has a Cyclically Adjusted Book per Share of €1.85 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Silence Therapeutics and its competitors.
Is Silence Therapeutics' Cyclically Adjusted Book per Share too high?
Silence Therapeutics' current Cyclically Adjusted Book per Share is €1.85. Overall, Silence Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Cyclically Adjusted Book per Share compare to IMRX and VRXA?
Silence Therapeutics' Cyclically Adjusted Book per Share of €1.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Cyclically Adjusted Book per Share is €1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (STU:XRP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.28, compared to a current price of €8.40 — trading 2900% above its estimated fair value. The current Cyclically Adjusted Book per Share is €1.85. Silence Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Silence Therapeutics (STU:XRP2), the current Cyclically Adjusted Book per Share is €1.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (STU:XRP2) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of €8.40 is trading 2900% above its estimated GF Value™ of €0.28. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:XRP2:

  • Cyclically Adjusted Book per Share: €1.85
  • GF Value™: €0.28 vs. price of €8.40 (2900% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the STU:XRP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Silence Therapeutics Business Description

Other Exchanges SLN:USASLNCF:USA
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
51GF Score

Get the complete analysis for STU:XRP2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.40
Price
€0.28
GF Value